Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ulcerative colitis remission status after induction with mesalazine predicts maintenance outcomes: The MOMENTUM trial
Journal of Crohn's and Colitis, Volume 10, No. 8, Year 2016
Notification
URL copied to clipboard!
Description
Background and Aims: This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine. Methods: In this phase 3b/4, open-label, multicentre, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8 g/day once daily for 8 weeks [induction phase]. At Week 8, those who achieved complete or partial remission, based on predefined clinical and endoscopic criteria, were eligible to receive 12 months of multimatrix mesalazine 2.4 g/day once daily maintenance therapy. The primary endpoint was the proportion of patients in complete remission at Month 12. Results: A total of 717 patients received induction treatment; 25.9% and 39.3% of patients achieved complete and partial remission, respectively, at Week 8. A total of 461 patients entered the maintenance phase. The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission [47.8% vs 26.0%; p < 0.001]. At Month 12, mucosal healing [endoscopy score ≤ 1] was demonstrated in 76.4% [139/182] and 63.5% [176/277] of those who were in complete and partial remission, respectively, at the end of induction. Conclusion: Patients achieving complete remission before dose reduction were more likely to remain in remission at Month 12. © European Crohn's and Colitis Organisation 2016.
Authors & Co-Authors
Rubin, David T.
United States, Chicago
The University of Chicago Medicine
D'Haens, Geert R.A.M.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Baert, Filip J.
Unknown Affiliation
Marshall, John Kenneth
Unknown Affiliation
Vaňásek, Thomas
Unknown Affiliation
Bourreille, Arnaud
Unknown Affiliation
Zerbib, Frank
Unknown Affiliation
Kucharzik, Torsten F.
Unknown Affiliation
Banerjee, Rupa
Unknown Affiliation
Bhandarkar, Prashant
Unknown Affiliation
Shenoy, Kotacherry Trivikrama
Unknown Affiliation
Sood, Ajit K.
Unknown Affiliation
O'Morain, Colm A.
Unknown Affiliation
Patchett, Stephen E.
Unknown Affiliation
Petryka, Robert
Unknown Affiliation
Gheorghe, Liana Simona
Unknown Affiliation
Goldiş, Adrian Eugen
Unknown Affiliation
Aboo, Nazimuddin
Unknown Affiliation
van Rensburg, Christoffel Johannes
Unknown Affiliation
Wright, John P.
Unknown Affiliation
Gisbert, Javier Pérez
Unknown Affiliation
Travis, Simon P.L.
Unknown Affiliation
Loftus Jr., Edward V.
Unknown Affiliation
Statistics
Citations: 24
Authors: 23
Affiliations: 6
Identifiers
Doi:
10.1093/ECCO-JCC/JJW049
ISSN:
18739946
Study Design
Cohort Study